NCT05475184进行中（未招募）2 期
A Multicenter, Open-label, Single-arm, Phase 2 Study to Evaluate the Efficacy and Safety of JPI-547, a PARP/TNKS Dual Inhibitor in Platinum-resistant, Advanced/Relapsed Ovarian Cancer Subjects Previously Treated With a PARP Inhibitor
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 入组人数
- 58
- 试验地点
- 1
- 主要终点
- Objective Response Rate(ORR)
研究概览
简要总结
To evaluate the efficacy and safety of JPI-547, a PARP/TNKS dual inhibitor in Platinum-resistant, advanced/relapsed ovarian cancer subjects previously treated with a PARP inhibitor
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 19 Years 至 —（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •Patients with advanced/metastatic high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer*:
- •who has undergone ≥2 previous chemotherapy regimen;
- •with confirmed platinum resistance**;
- •≥3 month PARP inhibitor treatment history;
- •confirmed BRCA1/2 mutation *** or HRD ****
- •Subjects with at least one measurable lesion in accordance with RECIST v1.1
- •Patients with Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1
- •Subjects with life expectancy ≥12 weeks
- •Patients with adequate hematologic, kidney, and liver functions confirmed using the following criteria (retesting of laboratory tests is allowed once during screening)
- •Subjects who voluntarily decided to participate in this study after being fully informed and gave informed consent
排除标准
- •Subjects who meet any of the following conditions cannot participate in this study:
- •Subjects with a history of severe drug hypersensitivity or the hypersensitivity to IP and its ingredients or similar drugs
- •Subjects with dysphagia
- •Subjects confirmed with the following medical or surgical/procedural history:
- •Primary malignant tumor other than ovarian cancer diagnosed or treated within 24 months prior to baseline (individuals with successfully treated cutaneous basal/squamous cell carcinoma are eligible for enrollment)
- •Major surgery requiring general anesthesia or respiratory support within 4 weeks prior to baseline (2 weeks for video-assisted thoracoscopic surgery [VATS] or open-and-closed [ONC] surgery)
- •Severe cardiovascular disease (e.g., myocardial infarction and unstable angina) that occurred within 24 weeks prior to baseline
- •New York Heart Association Class 3 or 4 heart failure within 24 weeks prior to baseline
- •Severe cerebrovascular disease observed within 24 weeks prior to baseline
- •Pulmonary thrombosis or deep vein thrombosis within 24 weeks prior to baseline, or bronchial asthma, obstructive pulmonary disease, or other serious, life-threatening lung disease (e.g., acute respiratory distress syndrome and lung failure) considered ineligible for study participation
- •Infections requiring treatment, such as systemic antibiotics and antivirals, within 2 weeks prior to baseline, or other uncontrolled ≥Grade 3 active infectious diseases
- •Symptomatic interstitial lung disease
- •Subjects who showed poor recovery from hematologic toxicity in the past chemotherapy (e.g., ≥grade 3 toxicity for ≥4 weeks)
- •Bone marrow or stem cell transplantation with high-dose chemotherapy
- •Total gastrectomy or total duodenectomy
- •Individuals with a history of myelodysplastic syndrome (MDS) or pretreatment cytogenetic test results indicating a risk of MDS/acute myeloid leukemia (AML) 4) Subjects with the following concurrent conditions:
- •Subjects with clinically significant symptoms or uncontrolled central nervous system or brain metastases (except when systemic corticosteroid administration was stopped at least 4 weeks prior to baseline and was stable for ≥4 weeks)
- •Subjects who have confirmed clinically significant conditions in the electrocardiogram (ECG) according to the investigator's judgment
- •Uncontrolled hypertension (systolic blood pressure >150 mmHg or diastolic blood pressure >90 mmHg)
- •Bleeding diatheses
- •Active hepatitis B or C virus infection (patients with hepatitis may participate if HBV DNA and HCV RNA are below the lower limit of detection established by the study site)
- •Known human immunodeficiency virus infection (HIV) positive
- •Subjects with neurological and psychiatric disorders severe enough to affect the study results according to the investigator's judgment 5) Subjects who have the following drug treatment history:
- •Subjects who have received chemotherapy†, immunotherapy (including biologics), hormone therapy, or therapeutic/palliative radiotherapy‡ within 4 weeks prior to baseline
- •Subjects who require continuous (≥4 weeks) treatment of systemic corticosteroids equivalent to prednisone >10 mg/day
- •Subjects who were treated with antithrombotic drugs, including antiplatelet agents and anticoagulants, within 2 weeks from baseline or are expected to be treated with them during the study period (however, low molecular weight heparin [LMWH]) treatment is allowed)
- •Subjects who require continuous administration of non-steroidal anti-inflammatory drugs (NSAIDs), which have high risk of bleeding 6) Pregnant or lactating women, or women of childbearing potential who do not intend to abstain or use appropriate contraceptive methods* during the study period and up to 3 months after IP administration *Appropriate contraception: 7) Subjects who have taken or undergone another IP or investigation device within 4 weeks prior to baseline 8) subjects who are judged by the investigator as ineligible for study participation
研究组 & 干预措施
JPI-547
Experimental
干预措施: JPI-547 (Drug)
结局指标
主要结局
Objective Response Rate(ORR)
时间窗: From date of study enroll until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months
To evaluate the objective response rate (ORR) in accordance with the Response Evaluation Criteria In Solid Tumors (RECIST) version 1.1.
次要结局
- Anti-tumor activity(From date of study enroll until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 40 months)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
A Study to Evaluate Safety and Efficacy of Toreforant (JNJ-38518168) in Participants With Moderate to Severe Plaque-type PsoriasisPsoriasisNCT02295865Janssen Research & Development, LLC62
撤回
2 期
Study to Evaluate Efficacy and Safety of JTT-251 in Participants With Pulmonary Arterial HypertensionPulmonary Arterial HypertensionNCT03789643Akros Pharma Inc.
撤回
2 期
A Dose Range Finding Study of JNJ-39758979 in Patients With Active Rheumatoid Arthritis Currently Treated With MethotrexateActive Rheumatoid Arthritis Rheumatoid ArthritisNCT01480388Janssen Research & Development, LLC
撤回
2 期
Study of JNJ-39758979 in Symptomatic Adult Patients With Uncontrolled AsthmaAsthmaNCT01493882Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
已完成
1 期
Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese ParticipantsHealthyNCT02835508Janssen Pharmaceutical K.K.18